The AUTACE That Degrades KRAS and Engages CD8 <sup>+</sup> T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors
T-cell recruitment and amplifying antitumor responses. Thus, AUTACE represents a promising strategy for the treatment of KRAS/TP53 co-mutant tumors.
Authors
- Chang Li (ORCID: https://orcid.org/0000-0002-3267-1859)
- Ying Tang (ORCID: https://orcid.org/0000-0001-9685-3152)
- Bo Pang (ORCID: https://orcid.org/0000-0002-7408-1355)
- Bing Li (ORCID: https://orcid.org/0000-0001-9413-6598)
- Yanan Hao
- Pan Li
Institutions
- Chongqing Maternal and Child Health Hospital (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Children's Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2026-04-07
- DOI
- https://doi.org/10.1002/advs.202518455
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Postdoctoral Science Foundation
- Natural Science Foundation of Chongqing
- Chongqing Municipal Education Commission